Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter October 1, 2015

Systemic administration of WY-14643, a selective synthetic agonist of peroxisome proliferator activator receptor-alpha, alters spinal neuronal firing in a rodent model of neuropathic pain

Bright N. Okine, Clare Spicer, Paul Millns, Andrew Bennett and Victoria Chapman

Abstract

Background and aims

The clinical management of chronic neuropathic pain remains a global health challenge. Current treatments are either ineffective, or associated with unwanted side-effects. The development of effective, safe therapies requires the identification of novel therapeutic targets using clinically relevant animal models of neuropathic pain.

Peroxisome proliferator activated receptor alpha (PPARα), is a member of the nuclear hormone family of transcription factors, which is widely distributed in the peripheral and central nervous systems. Pharmacological studies report antinociceptive effects of PPARα agonists following systemic administration in rodent models of neuropathic pain, however the neuronal mechanisms and sites of action mediating these effects are unclear.

The aim of this study was to investigate the effects of systemic administration of the synthetic PPARα agonist, WY-14643 on mechanically-evoked responses of spinal cord dorsal horn wide dynamic range (WDR) neurones in the spinal nerve ligated (SNL) model of neuropathic pain in rats. In addition, comparative molecular analysis of mRNA coding for PPARα and PPARα protein expression in the spinal cord of sham-operated and neuropathic rats was performed.

Methods

Lumbar L5–L6 spinal nerve ligation was performed in male Sprague–Dawley rats (110–130 g) under isoflurane anaesthesia. Sham controls underwent similar surgical conditions, but without ligation of the L5–L6 spinal nerves. Hindpaw withdrawal thresholds were measured on the day of surgery -day 0, and on days- 2, 4, 7, 10 and 14 post-surgery. At day 14 extracellular single-unit recordings of spinal (WDR) dorsal horn neurons were performed in both sham and SNL neuropathic rats under anaesthesia. The effects of intraperitoneal (i.p.) administration of WY-14643 (15 and 30 mg/kg) or vehicle on evoked responses of WDR neurons to punctate mechanical stimulation of the peripheral receptive field of varying bending force (8–60 g) were recorded. In a separate cohort of SNL and sham neuropathic rats, the expression of mRNA coding for PPARα and protein expression in the ipsilateral and contralateral spinal cord was determined using quantitative real time polymerase chain reaction (qRT-PCR) and western blotting techniques respectively.

Results

WY-14643 (15 and 30mg/kg i.p.) rapidly attenuated mechanically evoked (8, 10 and 15g) responses of spinal WDR neurones in SNL, but not sham-operated rats. Molecular analysis revealed significantly increased PPARα protein, but not mRNA, expression in the ipsilateral spinal cord of SNL, compared to the contralateral side in SNL rats. There were no changes in PPARα mRNA or protein expression in the sham controls.

Conclusion

The observation that levels of PPARα protein were increased in ipsilateral spinal cord of neuropathic rats supports a contribution of spinal sites of action mediating the effects of systemic WY-14643. Our data suggests that the inhibitory effects of a PPARα agonist on spinal neuronal responses may account, at least in part, for their analgesic effects of in neuropathic pain.

Implication

Selective activation of PPARα in the spinal cord may be therapeutically relevant for the treatment of neuropathic pain.


DOI of refers to article: http://dx.doi.org/10.1016/j.sjpain.2015.08.006.



Pharmacology and Therapeutics, School of Medicine, National University of Ireland Galway, University Road, Galway, Ireland. Tel.: +353 091495246

  1. Conflict of interest: None.

Acknowledgements

BNO was supported by a Medical Research Council studentship.

References

[1] Arner S, Meyerson BA. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain 1988;33:11–23.10.1016/0304-3959(88)90198-4Search in Google Scholar

[2] Benani A, Heurtaux T, Netter P, Minn A. Activation of peroxisome proliferator-activated receptoralpha in rat spinal cord after peripheral noxious stimulation. Neurosci Lett 2004;369:59–63.10.1016/j.neulet.2004.07.056Search in Google Scholar

[3] BenaniA, Kremarik-Bouillaud P, Bianchi A, Netter P, Minn A, Dauca M. Evidence for the presence of both peroxisome proliferator-activated receptors alpha and beta in the rat spinal cord.J Chem Neuroanat 2003;25:29–38.10.1016/S0891-0618(02)00093-5Search in Google Scholar

[4] Bennett GJ, Xie YK.Aperipheral mononeuropathy in ratthat producesdisorders of pain sensation like those seen in man Pain 1988;33:87–107.10.1016/0304-3959(88)90209-6Search in Google Scholar

[5] Bettoni 1, Comelli F, Colombo A, Bonfanti P, Costa B. Non-neuronal cell modulation relieves neuropathic pain: efficacy of the endogenous lipid palmitoylethanolamide. CNS Neurol Disord Drug Targets 2013;12:34–44.10.2174/1871527311312010008Search in Google Scholar

[6] Blanquart C, Barbier O, Fruchart JC, Staels B, Glineur C. Peroxisome proliferator-activated receptor alpha (PPARalpha) turnover by the ubiquitin-proteasome system controls the ligand-induced expression level of its target genes. J Biol Chem 2002;277:37254–9.10.1074/jbc.M110598200Search in Google Scholar

[7] Blanquart C, Mansouri R, Fruchart J-C, Staels B, Glineur C. Different ways to regulate the PPARα stability. Biochem Biophys Res Commun2004;319:663–70.10.1016/j.bbrc.2004.05.035Search in Google Scholar

[8] Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 1996;137:354–66.10.1210/endo.137.1.8536636Search in Google Scholar

[9] Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment oftactile allodynia in the rat paw. J Neurosci Methods 1994;53:55–63.10.1016/0165-0270(94)90144-9Search in Google Scholar

[10] Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors and inflammation: from basic science to clinical applications. Int J Obes Relat Metab Disord 2003;27:S41–5.10.1038/sj.ijo.0802499Search in Google Scholar

[11] Clark AK, Yip PK, Grist J, Gentry C, Staniland AA, Marchand F, Dehvari M, Wotherspoon G, Winter J, Ullah J, Bevan S, Malcangio M. Inhibition of spinal microglial cathepsin S for the reversal of neuropathic pain. Proc Natl Acad Sci USA 2007;104:10655–60.10.1073/pnas.0610811104Search in Google Scholar

[12] CohenSP, MaoJ. Neuropathic pain: mechanisms and their clinical implications. BMJ 2014;348.10.1136/bmj.f7656Search in Google Scholar

[13] Costa B, Comelli F, Bettoni 1, Colleoni M, Giagnoni G. The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB (1), TRPV1 and PPARgamma receptors and neurotrophic factors. Pain 2008;139: 541–50.10.1016/j.pain.2008.06.003Search in Google Scholar

[14] Cuzzocrea S, Bruscoli S, Mazzon E, Crisafulli C, Donato V, Di Paola R, Velardi E, Esposito E, Nocentini G, Riccardi C. Peroxisome proliferator-activated receptor- alpha contributes to the anti-inflammatory activity of glucocorticoids. Mol Pharmacol 2008;73:323–37.10.1124/mol.107.041475Search in Google Scholar

[15] de Novellis V, Luongo L, Guida F, Cristino L, Palazzo E, Russo R, Marabese 1, D’Agostino G, Calignano A, Rossi F, Di Marzo V, Maione S. Effects of intra- ventrolateral periaqueductal grey palmitoylethanolamide on thermoceptive threshold and rostral ventromedial medulla cell activity. Eur J Pharmacol 2012;676:41–50.10.1016/j.ejphar.2011.11.034Search in Google Scholar

[16] Di Cesare Mannelli L, D’Agostino G, Pacini A, Russo R, Zanardelli M, Ghelardini C, Calignano A. Palmitoylethanolamide is a disease-modifying agent in peripheral neuropathy: pain relief and neuroprotection share a PPAR-alpha-mediated mechanism. Mediators Inflamm 2013;2013:328797.10.1155/2013/328797Search in Google Scholar

[17] Gao Y-J, Zhang L, Samad OA, Suter MR, Yasuhiko K, Xu Z-Z, Park J-Y, Lind A-L, Ma Q, Ji R-R. JNK-induced MCP-1 production in spinal cord astrocytes contributes to central sensitization and neuropathic pain. J Neurosci 2009;29: 4096–108.10.1523/JNEUROSCI.3623-08.2009Search in Google Scholar

[18] Jhaveri MD, Richardson D, Kendall DA, Barrett DA, Chapman V. Analgesic effects of fatty acid amide hydrolase inhibition in a rat model of neuropathic pain. J Neurosci 2006;26:13318–27.10.1523/JNEUROSCI.3326-06.2006Search in Google Scholar

[19] Jin SX, Zhuang ZY, Woolf CJ, Ji RR. p38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain.J Neu- rosci 2003;23:4017–22.10.1523/JNEUROSCI.23-10-04017.2003Search in Google Scholar

[20] Kiguchi N, Maeda T, Kobayashi Y, Fukazawa Y, Kishioka S. Macrophage inflammatory protein-1alpha mediates the development of neuropathic pain following peripheral nerve injury through interleukin-1beta up-regulation. Pain 2010;149:305–15.10.1016/j.pain.2010.02.025Search in Google Scholar

[21] Kim SH, Chung JM. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 1992;50:355–63.10.1016/0304-3959(92)90041-9Search in Google Scholar

[22] LoeserJD, Treede RD. The Kyoto protocol oflASP Basic Pain Terminology. Pain 2008;137:473–7.10.1016/j.pain.2008.04.025Search in Google Scholar

[23] LoVerme J, La Rana G, Russo R, Calignano A, Piomelli D. The search for the palmitoylethanolamide receptor. Life Sci 2005;77:1685–98.10.1016/j.lfs.2005.05.012Search in Google Scholar

[24] LoVermeJ, Russo R, LaRana G, Fu J, Farthing J, Mattace-Raso G, Meli R, Hohmann A, Calignano A, Piomelli D. Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha.J Pharmacol ExpTher 2006;319:1051–61.10.1124/jpet.106.111385Search in Google Scholar

[25] Luongo L, Guida F, Boccella S, Bellini G, Gatta L, Rossi F, de Novellis V, Maione S. Palmitoylethanolamide reduces formalin-induced neuropathic-like behaviour through spinal glial/microglial phenotypical changes in mice. CNS Neurol Disord Drug Targets 2013;12:45–54.10.2174/1871527311312010009Search in Google Scholar

[26] Matsushita K, Tozaki-Saitoh H, Kojima C, Masuda T, Tsuda M, Inoue K, Hoka S. Chemokine (C-C motif) receptor 5 is an important pathological regulator in the development and maintenance of neuropathic pain. Anesthesiology 2014;120:1491–503.10.1097/ALN.0000000000000190Search in Google Scholar

[27] Mick G, Baron R, Correa-lllanes G, Hans G, Mayoral V, Frias X, Sintes D, KellerT. 1s an easy and reliable diagnosis oflocalized neuropathic pain (LNP) possible in general practice? Development of a screening tool based on 1ASP criteria. Curr Med Res Opin 2014;30:1357–66.10.1185/03007995.2014.907562Search in Google Scholar

[28] MikaJ, Osikowicz M, MakuchW, Przewlocka B. Minocycline and pentoxifylline attenuate allodynia and hyperalgesia and potentiate the effects of morphine in rat and mouse models of neuropathic pain. EurJ Pharmacol 2007;560:142–9.10.1016/j.ejphar.2007.01.013Search in Google Scholar

[29] Moreno S, Farioli-Vecchioli S, Ceru MP. Immunolocalization of peroxisome proliferator-activate receptors and retinoid X receptors in the adult rat CNS. Neuroscience 2004;123:131–45.10.1016/j.neuroscience.2003.08.064Search in Google Scholar

[30] Okine BN, Norris LM, Woodhams S, Burston J, Patel A, Alexander SP, Barrett DA, Kendall DA, Bennett AJ, Chapman V. Lack of effect of chronic pre-treatment with the FAAH inhibitor URB597 on inflammatory pain behaviour: evidence for plastic changes in the endocannabinoid system. BrJ Pharmacol 2012;167:627–40.10.1111/j.1476-5381.2012.02028.xSearch in Google Scholar

[31] Okine BN, Rea K, Olango WM, Price J, Herdman S, Madasu MK, Roche M, Finn DP. A role for PPARalpha in the medial prefrontal cortex in formalin-evoked nociceptive responding in rats. Br J Pharmacol 2014;171:1462–71.10.1111/bph.12540Search in Google Scholar

[32] Reinecke H, Weber C, Lange K, Simon M, Stein C, Sorgatz H. Analgesic efficacy of opioids in chronic pain: recent meta-analyses. Br J Pharmacol 2015;172:324–33.10.1111/bph.12634Search in Google Scholar

[33] Tatsumi E, Yamanaka H, Kobayashi K, Yagi H, Sakagami M, Noguchi K. RhoA/ROCK pathway mediates p38 MAPK activation and morphological changes downstream of P2Y12/13 receptors in spinal microglia in neuropathic pain. Glia 2015;63:216–28.10.1002/glia.22745Search in Google Scholar

[34] Terayama R, Omura S, Fujisawa N, Yamaai T, Ichikawa H, Sugimoto T. Activation of microglia and p38 mitogen-activated protein kinase in the dorsal column nucleus contributes to tactile allodynia following peripheral nerve injury. Neuroscience 2008;153:1245–55.10.1016/j.neuroscience.2008.03.041Search in Google Scholar

[35] Wang W, Wang W, Mei X, Huang J, Wei Y, Wang Y, Wu S, Li Y. Crosstalk between spinal astrocytes and neurons in nerve injury-induced neuropathic pain. PLoS ONE 2009;4:e6973.10.1371/journal.pone.0006973Search in Google Scholar

[36] Xu J, Chavis JA, Racke MK, Drew PD. Peroxisome proliferator-activated receptor-alpha and retinoid X receptor agonists inhibit inflammatory responses of astrocytes. J Neuroimmunol 2006;176:95–105.10.1016/j.jneuroim.2006.04.019Search in Google Scholar

[37] Xu J, Storer PD, Chavis JA, Racke MK, Drew PD. Agonists for the peroxisome proliferator-activated receptor-alpha and the retinoid X receptor inhibit inflammatory responses of microglia.J Neurosci Res 2005;81:403–11.10.1002/jnr.20518Search in Google Scholar

Received: 2015-05-25
Revised: 2015-06-09
Accepted: 2015-06-14
Published Online: 2015-10-01
Published in Print: 2015-10-01

© 2015 Scandinavian Association for the Study of Pain